Abstract
The COVID-19 pandemic, caused by tens of millions of SARS-CoV-2 infections world-wide, has resulted in considerable levels of mortality and morbidity. The United States has been hit particularly hard having 20 percent of the world’s infections but only 4 percent of the world population. Unfortunately, significant levels of misunderstanding exist about the severity of the disease and its lethality. As COVID-19 disproportionally impacts elderly populations, the false impression that the impact on society of these deaths is minimal may be conveyed by some because elderly individuals are closer to a natural death. To assess the impact of COVID-19 in the US, I have performed calculations of person-years of life lost as a result of 194,000 premature deaths due to SARS-CoV-2 infection as of early October, 2020. By combining actuarial data on life expectancy and the distribution of COVID-19 associated deaths we estimate that over 2,500,000 person-years of life have been lost so far in the pandemic in the US alone, averaging over 13.25 years per person with differences noted between males and females. Importantly, nearly half of the potential years of life lost occur in non-elderly populations. Issues impacting refinement of these models and the additional morbidity caused by COVID-19 beyond lethality are discussed.
Competing Interest Statement
Dr. Elledge is a founder of TSCAN Therapeutics, MAZE Therapeutics and Mirimus Inc. He serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE, X-Chem, and is an advisor for MPM, none of which impact this work.
Funding Statement
This work was supported by grants from the MassCPR and the Value of Vaccine Research Network to S.J.E. S.J.E. is an Investigator with the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N.A.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All Data used in this study is available in the tables in this paper or the links to the publicly available data.
https://coronavirus.jhu.edu/map.html
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm
https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
https://www.ssa.gov/oact/STATS/table4c6.html#fn1
https://www.census.gov/topics/population/age-and-sex/library/publications.2011.html
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities